Sanofi - American Depositary Shares (SNY)
$54.95
0.06 (0.11%)
SNY Stock Quote Delayed 30 Minutes
Once Slow, Stable Sanofi Stock is Now Pharma’s Most-Talked About Name
SNY stock is no longer a sleepy passive investment. Under a new CEO, Sanofi is less reliant on diabetes and heart drugs and looking to buy pre-market cancer blockbusters.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
68.73B
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
1.82M
Day's Range
$54.57 - $55.20
52-Week Range
$45.22 - $58.97
Dividend & Yield
$2.04 (3.71%)
SNY Stock Predictions, Articles, and Sanofi - American Depositary Shares News
Regeneron Pharmaceuticals Earnings: REGN Stock Drops on Q1 Miss
Regeneron Pharmaceuticals earnings for the first quarter of 2019 have REGN stock falling on Tuesday due to poor results for the period.
6 Pharmaceutical Stocks to Buy After the Midterms
The upside case for pharmaceutical stocks is building. The midterm elections results mean its unlikely drug price regulation will happen soon.
Why Sanofi Stock Should Run Higher Despite Mixed Earnings
SNY stock beat on earnings and missed on revenue, but sales of newer drugs as well as a low P/E and a high dividend show promise for Sanofi.
Sanofi SA Shares Slip on Falling Sales
Sanofi (SNY) stock was down Friday after the company released disappointing sales for its first-quarter 2018 earnings report.
Biotech M&A: Sanofi SA (ADR) Inks 2nd Multi-Billion Dollar Deal in a Week
Sanofi (SNY) inks second multi-dollar deal this month. Since the earlier deal last Monday, SNY stock gained 2.6% in a week.
Is MannKind Corporation Stock Really Worth the Risk?
Volatility has send MannKind stock's options prices through the roof. You could sell option premium here, but is MNDK worth the risk?
Why Investors Should Stay Long Eli Lilly and Co Stock
LLY stock had a sudden drop on Jan. 22, but Eli Lilly and Co recovered the bulk of its losses, which means bulls can stay long for the time being.
Sanofi (SNY) a Hold on Vapid Earnings Momentum
Sanofi SA (NYSE:SNY) is a constituent of the 134 company Pharmaceuticals GICS industry group, which is a segment of the 782 company GICS Health Care sector. SNY's market value is $112.1 billion which places it in the top 10% of its industry group. Portfolio Grader's current ranking for SNY puts it 53 among the 134 companies in this industry group, placing it in the top half; in the top half of the sector with a ranking of 307 among the 782 companies in the sector, and number 1,707 in the nearly 5,000 company Portfolio Grader universe.
Robust Quant Score Metrics Drive Ranking of Sanofi (SNY) to Buy
Sanofi SA (NYSE:SNY) is one of the 781 companies in the GICS Health Care sector, and a member of the 134 company Pharmaceuticals GICS industry group within this sector. The market value of SNY is $115.8 billion which falls in the top decile in its industry group. The ranking for SNY by Portfolio Grader places it 34 among the 134 companies in this industry group, giving it an above-average position; in the top half of the sector with a ranking of 206 among the 781 companies in the sector, and number 1,262 in the nearly 5,000 company Portfolio Grader universe.
Sanofi (SNY) Earnings Growth Hurt Rating
Portfolio Grader currently ranks Sanofi SA (NYSE:SNY) a Hold. The system for investing incorporated in this analytical tool developed by Louis Navellier assesses and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. SNY has recently seen its Portfolio Grader rating downgraded over the last month from a Buy to a Hold.
Drooping Earnings Growth Downgrades Sanofi (SNY) to Hold
Sanofi SA (NYSE:SNY) is a $113.0 billion in market value member of the Pharmaceuticals GICS industry group where the ranking for SNY by Portfolio Grader places it 39 among the 132 companies in this industry group, putting it in the second quartile. SNY is ranked in the top half of the sector with a ranking of 273 among the 782 companies in the sector and number 1,725 in the 5000 company Portfolio Grader company universe.
Sanofi (SNY) Shares a Buy on Earnings Momentum
Sanofi SA (NYSE:SNY) is a constituent of the 133 company Pharmaceuticals GICS industry group, which is part of the 785 company GICS Health Care sector. SNY's market value is $114.9 billion which falls in the top 10% of its industry group. Currently, the stock's Portfolio Grader ranking places it 29 among the 133 companies in this industry group, placing it among the leaders; in the top quartile of the sector with a ranking of 189 among the 785 companies in the sector, and number 1,216 in the nearly 5,000 company Portfolio Grader universe.
Eroding Analytics Drop Sanofi (SNY) to Buy
Sanofi SA (NYSE:SNY) is one of 133 companies within the Pharmaceuticals GICS industry group, which is in turn part of the 783 company GICS Health Care sector. The market value of SNY is $119.4 billion which places it in the top decile in its industry group. Portfolio Grader's current ranking for SNY puts it 14 among the 133 companies in this industry group, giving it a well above-average position; in the top quartile of the sector with a ranking of 84 among the 783 companies in the sector, and number 614 in the nearly 5,000 company Portfolio Grader universe.
High-Level Measures for Earnings Momentum Make Sanofi (SNY) a Strong Buy
The current recommendation of Strong Buy for Sanofi SA (NYSE:SNY) is the result of using the stock evaluator from Portfolio Grader, which incorporates Louis Navellier's investing approach. SNY has maintained this ranking for 2 months.
Sanofi (SNY) a Strong Buy on Outstanding Quant Score
Sanofi SA (NYSE:SNY) is classified as a member of the 135 company Pharmaceuticals GICS industry group, which is a segment of the 783 company GICS Health Care sector. SNY's market value is $124.3 billion which falls in the top decile in its industry group. The stock's current Portfolio Grader score places it 2 among the 135 companies in this industry group, positioning it among the leaders; among the sector leaders with a ranking of 18 among the 783 companies in the sector, and number 194 in the nearly 5,000 company Portfolio Grader universe.
